Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
(1) Background: In recent years, immunotherapy has revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), representing a therapeutic breakthrough in this field. Antacid agents such as proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are commonly presc...
Main Authors: | Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso, Gennaro Palmiotti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/6/1404 |
Similar Items
-
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
by: Alessandro Rizzo, et al.
Published: (2022-04-01) -
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
by: Krisztian Homicsko, et al.
Published: (2022-05-01) -
The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis
by: Yu Chang, et al.
Published: (2022-12-01) -
Comparison and Analysis of Delirium Induced by Histamine H2 Receptor Antagonists and Proton Pump Inhibitors in Cancer Patients
by: Shiro Fujii, et al.
Published: (2012-07-01) -
Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
by: Jean-Luc Raoul, et al.
Published: (2022-02-01)